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Summary  Invasive  meningococcal  disease  (IMD)  is  life-threatening  and  can  result
in  severe  sequelae.  In  France,  no  data  have  been  published  on  the  costs  of  severe
IMD  cases.  Two  realistic  scenarios  were  developed  with  national  experts  (clinicians
and  social  workers):  a  6-year-old  child  with  purpura  fulminans  with  amputation  of
both  legs  below  the  knee  (case  A)  and  a  3-year-old  with  meningitis  and  severe  neu-
rological  sequelae  (case  B).  Additional  scenarios  included  other  typical  sequelae
of  IMD  such  as  chronic  kidney  disease  (CKD),  profound  deafness  and  epilepsy.  Data
on  healthcare,  disability,  educational  and  other  resource  use  were  obtained  from
experts  and  families  of  patients  with  similar  sequelae.  Unit  costs  (2013)  were  mainly
obtained  from  the  literature  and  the  National  Health  Insurance  (NHI).  Time  horizon
was  based  on  life  expectancies  of  patients  (77  and  55  years,  respectively).  A  4%  dis-
count  rate  decreasing  to  2%  after  30  years  was  applied.  Costs  are  presented  from  the
perspective  of  the  NHI,  publicly  funded  organizations  and  patients’  families  or  their
private  health  insurances.  purpura  fulminans  with  amputations  is  associated  with  a
lifelong  discounted  cost  of  D  768,875.  Adding  CKD  doubles  the  amount  (D  1,480,545).
Meningitis  with  severe  neuro-cognitive  sequelae  results  in  a  lifelong  discounted  cost
of  D  1,924,475.  Adding  profound  deafness  and  epilepsy  slightly  increases  the  total
cost  (D  2,267,251).  The  ﬁrst  year  is  the  most  expensive  in  both  scenarios  (D  166,890
Abbreviations: CKD, chronic kidney disease; IMD, invasive meningococcal disease; MRF, Meningitis Research Foundation; NHI,
ational Health Insurance; PICU, Pediatric Intensive Care Unit.
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Introduction
Invasive  meningococcal  disease  (IMD)  is  a  severe
bacterial  infection  caused  by  Neisseria  meningitidis
or meningococcus,  the  most  disease-associated
serogroups  being  A,  B,  C,  W  and  Y.  Young
non-immunized  children  are  the  most  at  risk
of contracting  the  disease.  IMD  can  present  as
meningococcal  septicemia,  which  can  evolve  to
purpura fulminans, very  serious  septic  shock  or
meningitis  [1]. The  disease  can  result  in  severe
sequelae and  is  fatal  in  50—80%  of  cases  if  not
treated [2—4].  Even  when  treated,  5—10%  of  the
patients die  24—48  h  after  the  onset  of  symptoms
[2].  This  rate  is  even  higher  for  patients  with  pur-
pura fulminans  (15—30%)  [5,6].  Sequelae  include
cerebral lesions,  hearing  loss,  learning  difﬁcul-
ties in  10—20%  of  survivors,  deafness  in  3—15%
and severe  cognitive  deﬁcits,  cerebral  palsy  or
epilepsy  in  rare  cases  (3—4%)  [7,8]. Of  the  ini-
tial survivors,  10—30%  present  with  skin  necrosis
and limb  ischemia  requiring  orthopedic  surgical
management, such  as  debridement,  skin  grafting,
muscular  ﬂap  coverage  for  limb  salvage  and  some-
times even  limb  amputation  [6].
The  introduction  of  meningococcal  conjugate
vaccines in  the  last  20  years  has  resulted  in  a  reduc-
tion  in  the  incidence  of  IMD  across  Europe  [5].
In France,  the  incidence  of  IMD  has  been  sta-
ble for  the  last  25  years  and  is  approximately  1
case per  100,000  inhabitants.  There  is  a  high  pre-
dominance  of  serogroup  B  (58%)  and  C  (26%)  [9],
and the  incidence  of  IMD  in  France  remains  rela-
tively high  compared  to  other  European  countries
such as  Italy  or  Germany.  The  very  ﬁrst  vaccine
to protect  against  different  strains  of  serogroup
B meningococcal  bacteria,  Bexsero®,  became  a
licensed  product  in  January  2013  and  is  indicated
for children  2 months  of  age  in  Europe.  More
recently in  the  USA,  the  FDA  granted  a  license  to
® ®Bexsero and  to  another  vaccine  Trumenba ,  both
of which  are  indicated  for  those  10—25  years  of  age.
At the  time  of  writing,  the  UK  is the  only  European
country [10]  to  have  started  vaccinating  infants
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 The  main  cost  drivers  for  each  scenario  are  prostheses
hcare  facilities,  respectively.  Overall,  patients’  families
o  pay  around  13%  of  total  cost  (101,833D  and  258,817D  ,
a gap  in  the  body  of  knowledge  on  IMD  sequelae  care  and
 potentially  high  economic  burden  of  IMD,  in  addition  to
d  social  burden,  reinforces  the  need  for  prevention.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
gainst  serogroup  B  disease  as  part  of  children’s
outine immunization  schedule.
To date,  very  little  data  have  been  published
oncerning the  ﬁnancial  impact  of  IMD,  and  no  data
re available  for  France,  particularly  in  regards
o the  different  payer  perspectives  throughout
 patient’s  lifetime.  Therefore,  we  speciﬁcally
esigned this  study  to  estimate  the  cost  of  exhaus-
ive resource  consumption  of  two  severe  and
ealistic scenarios  of  IMD  cases  and  their  sequelae
n France,  from  the  onset  of  symptoms  to  the  end
f life,  from  all  payers’  perspectives.
aterials and methods
cenario development
e  developed  two  scenarios  of  severe  IMD  cases:
 6-year-old  boy  with  purpura  fulminans  result-
ng in  amputation  of  both  legs  below  the  knee
case A)  and  a 3-year-old  girl  with  menin-
itis resulting  in  severe  neurological  sequelae
case B).  Additional  scenarios  were  created  to
nclude other  common  sequelae  of  IMD.  Sce-
arios were  initially  based  on  those  previously
elected in  a UK  study  [11]  and  were  then  adapted
o France  with  the  help  of  national  experts.
arious healthcare  specialists  (pediatricians,  ortho-
edic surgeons,  neurosurgeons,  physical  therapists,
ephrologists,  otolaryngologists,  prosthesis  spe-
ialists, social  workers,  occupational  therapists,
sychomotor specialists,  and  independent  living
pecialist)  and  families  of  patients  with  seque-
ae similar  to  those  of  patients  A  and  B  were
nterviewed to  describe  and  evaluate  patient  man-
gement.  In  total,  19  healthcare  professionals,  5
atient’s families  and  one  patient  group  agreed
o participate  in  face-to-face  or  telephone  meet-
ngs. Lifelong  patient  management  was  described
n the  interviews  and  all  resource  use  associated
ith each  step  of  management  was  collected.  For
ach family,  hypothetical  revenues,  type  of  home
nd distance  from  home  to  healthcare  profession-
ls were  determined.  The  time  horizon  was  based
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Table  1  Costs  included  in  the  analysis.
Type  of  cost  Resources
Direct
medical  costs
Consultations
Transports
Hospitalizations
Rehabilitation  center
Drugs
Prostheses,  wheelchairs,  crutches,
pressure  garments,  medicalized
stroller,  support  corset,  cochlear
implants,  diapers
Indirect
medical  costs
(prevention
for  contacts
and  social
expenses)
Biological  tests
Blood  sampling
Public  health  doctor  salary
Chemoprophylaxis
Vaccines  and  drugs
Accommodation  for  parents
Accommodation  and  car  adaptation
Salary  of  personal  assistant
Salary  of  educational  assistant
Pediatric  residential  unit
Full-time  residential  care
Mother’s  revenue  loss
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patient to  obtain  ﬁnancial  aid  for  the  costs  of  careIndirect  costs Financial  aids
n  life  expectancy  estimates  (respectively  77  and
5 years  for  cases  A  and  B).
osts
ll  costs  are  expressed  in  euros  (D  ) based  on  their
013 value.  Direct  medical  and  non-medical  costs
s well  as  indirect  costs  were  included  (Table  1).
ncome  loss  was  calculated  for  the  parents  only,
nd productivity  loss  due  to  the  patients’  lifetime
isability  was  not  included.  The  costs  were  dis-
ounted  according  to  the  methodological  guide  for
ealth economic  evaluation  provided  by  the  French
ational  Authority  for  Health  (Haute  Autorité  de
anté, HAS)  [12].  Accordingly,  a  4%  discount  rate
hat decreased  to  2%  after  30  years  was  applied.
The cost  of  resource  consumption  was  calcu-
ated using  French  cost  repositories  and  was  mainly
btained  from  the  literature  and  National  Health
nsurance  (NHI)  data.
nalyses
or  each  scenario,  the  following  outcomes  were
stimated by  type  of  expense  and  by  type  of payer: discounted  and  undiscounted  total  cost  of  IMD
from symptom  onset  to  patient  death,  and
 discounted  and  undiscounted  annual  mean  cost.
a
h
t341
Sensitivity  analyses  were  performed  for  param-
ters in  which  there  was  uncertainty  using  lower
nd upper  boundary  estimates.  Analyses  were  per-
ormed from  the  perspective  of  the  NHI,  publicly
unded organizations  and  patients  or  their  private
ealth  insurances.
esults
atient A
ase  A
atient  A  contracted  IMD  with  purpura  fulminans
t 6  years  old,  experiencing  fever  and  a skin  rash.
fter  a  ﬁrst  outpatient  visit  with  a pediatrician,  he
as transported  by  ambulance  to  the  nearest  hospi-
al. After  several  examinations,  he  was  transferred
y helicopter  to  the  nearest  university  hospital,
here he  was  cared  for  in  the  Pediatric  Intensive
are Unit  (PICU)  for  septic  shock  associated  with
espiratory  distress  syndrome  requiring  mechanical
entilation. He  had  necrosis  of  the  limb  extremi-
ies, which  led  to  amputation  of  both  legs  below
he knees.  After  a  1-month  stay  at  the  PICU,  the
atient  was  transferred  to  the  pediatric  ward  where
e stayed  for  an  additional  month  while  undergoing
kin debridement  operations  and  dressing  changes.
uring  his  stay,  his  parents  stayed  in  the  hospital’s
arents House.
Blood analysis  was  performed  to  identify  the
acterium responsible  for  the  infection.  After  the
erogroup  C  meningococcus  was  identiﬁed,  chemo-
rophylaxis  was  prescribed  to  close  contacts  of
he patient  (primary  school,  family  and  friends)
o avoid  bacterial  transmission  and  development
f other  cases.  Additionally,  these  close  contacts
ere vaccinated  with  a tetravalent  A,  C,  Y,  W135
onjugate  vaccine.
After  being  discharged  from  the  hospital,  patient
 was  transferred  to  a  rehabilitation  center  for  4
onths, which  he  attended  5  days  a week,  where
e was  cared  for  by  an  occupational  therapist.
nce his  wounds  started  to  heal,  patient  A  received
kin grafts  to  repair  the  dermatologic  damage
n his  remaining  limbs,  which  required  an  addi-
ional 1-week  hospital  stay.  Additionally,  once  the
mputated  areas  were  healed,  the  patient  began
o receive  specialized  equipment.  A  ﬁle  at  the
epartmental  House  for  Disability  (Maison  Départe-
entale  du  Handicap,  MDPH)  was  created  for thend support  that  were  not  reimbursed  by public
ealth insurance  through  the  Disability  Compensa-
ion (Prestation  Compensatoire  du  Handicap,  PCH).
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The  rehabilitative  care  physician  also  prepared
a report  to  provide  evidence  of  chronic  disease
(Affection Longue  Durée,  ALD),  which  enabled  the
patient to  receive  a  100%  reimbursement  for  his
medical care.
After patient  A  returned  home,  the  pediatri-
cian coordinated  his  care  and  visits  to  specialist
health professionals  (e.g.,  physiatrist,  orthope-
dic surgeon,  orthoprosthetist,  physical  therapist,
and psychomotor  specialist).  A  home  helper  was
employed  for  3  months.  Daily  nursing  care  was  con-
tinued  at  home  because  of  the  patient’s  superﬁcial
necrosis. Additionally,  his  skin  grafts  were  asso-
ciated  with  receiving  physical  therapy.  Patient  A
underwent  two  subsequent  operations  because  of
post-amputation  complications  (bone  overgrowth
from stump).  Prostheses  were  regularly  reviewed
and replaced  to  correspond  to  patient’s  growth  and
the evolution  of  his  needs.  Liners  and  sockets  were
regularly  replaced.  The  patient  required  crutches
and a  manual  wheelchair  for  mobility.  Additionally,
pressure garments  following  skin  grafts  were  nec-
essary for  2  years.  He  was  active  and  needed  a
sports wheelchair  throughout  his  life.  Patient  A  was
absent from  school  during  his  6-month  hospitaliza-
tion and  went  back  to  school  with  an  educational
assistant until  he  entered  secondary  school.  A  taxi
that was  paid  for  by  the  Region  Council  provided  his
transport  between  home  and  school.  Transportation
between the  rehabilitation  center  and  the  patient’s
home  was  included  in  the  daily  cost  of  the  rehabil-
itation center.  Finally,  the  transportation  expenses
associated  with  visiting  health  professionals  that
were made  by  the  patient’s  family  car  or  by  taxi
were covered  by  the  NHI.
Patient  A  was  one  of  3  children  in  a two-
parent household.  Before  becoming  ill,  his  mother
used to  work  full-time  and  earned  the  minimum
French salary;  his  father  was  also  working  full-time
and earned  the  mean  French  salary.  When  patient
A became  ill,  his  mother  stopped  working  for  6
months,  after  which  she  worked  part-time.  Because
of their  ﬁnancial  situation,  the  patient’s  family  ben-
eﬁted from  parental  leave  payments  for  6  months
and then  from  basic  Handicapped  Child  Education
Aid (Allocation  d’Education  de  l’Enfant  Handicapé,
AEEH) payments  until  the  patient  turned  20  years
old. At  18  years  old,  patient  A  continued  his  studies
for 3  more  years.  At  21  years  old,  he  found  full-time
work in  an  ofﬁce  and  lived  independently.  A  home
helper  visited  him  for  7  h  each  week.  He  retired  at
55 and  died  at  77.An  alternative  scenario  was  created  in  which
patient A  developed  chronic  kidney  disease
(CKD) after  the  episode  of  purpura  fulminans,
which worsened  after  several  years  and  required
s
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emodialysis.  In this  scenario,  patient  A  needed  4
idney transplants  throughout  his  life.
osts related  to  case  A
he total  discounted  cost  was  D  768,875  (lower
ound: D  585,025;  upper  bound:  D  959,964)
Table  2).  With  the  addition  of  acute  kidney  injury
esulting  in  CKD  to  the  initial  scenario,  which
equired repeated  renal  grafts  throughout  the
atient’s  life,  the  total  discounted  cost  doubled
rom D  768,875  to  D  1,480,546.
In the  initial  scenario,  the  most  important  driver
f cost  was  the  cost  of the  prostheses  (D  281,595;
6.6%). Half  of  the  total  discounted  cost  was  cov-
red by  the  NHI  (D  394,501;  51.3%).  The  next  largest
ercentage  of  the  total  cost  was  covered  by  publicly
unded  organizations  (D  272,541;  35.4%),  followed
y the  patient’s  family  and/or  its  private  insurance
D 101,833;  13.2%).  The  main  expense  for  the  NHI
as the  cost  of  the  prostheses  (D  281,595;  71.4%),
hereas  it was  child  education  for  the  publicly
unded organizations  (D  100,315;  36.9%)  and  par-
nts’ revenue  loss  for  the  patient  and/or  private
nsurance (D  55,661;  54.7%).
In the  occurrence  of  kidney  disease,  the  largest
roportion of  the  total  cost  was  covered  by
he NHI  (D  1,106,033;  74.7%),  followed  by pub-
icly funded  organizations  (D  272,541;  18.4%)  and
y the  patient’s  family  and/or  private  insurance
D 101,972;  6.9%).  Most  of  the  additional  costs
elated to  kidney  disease  were  paid  for  by  the  NHI.
The mean  annual  discounted  total  cost  was
 10,679  (lower  bound:  D  8125;  upper  bound:
 13,333).  The  ﬁrst  year  represented  21.7%  of  the
otal cost  and  was  the  year  with  the  highest  cost
D 166,890)  because  of  the  initial  hospitalization,
ehabilitative  care  and  purchase  of  specialized
quipment (Fig.  1).  When  acute  kidney  injury  and
KD were  added,  the  mean  annual  discounted  cost
otaled D  20,563  (lower  bound:  D 18,010;  upper
ound: D  23,217).
atient B
ase  B
atient  B  contracted  bacterial  meningitis  at  3
ears old,  suffering  fever,  petechiae  and  loss  of
onsciousness.  After  a ﬁrst  consultation  with  a
ediatrician,  she  was  transported  by  ambulance
o the  nearest  university  hospital,  where  she  was
ared for  in  the  PICU,  managed  hemodynamically
nd mechanically  ventilated.  However,  patient  B
tarted to  convulse  and  presented  with  severe
ncephalitic complications.  This  resulted  in  cog-
itive deﬁciencies,  complete  hemiplegia,  lateral
omonymous  hemianopsia,  behavioral  disorder  and
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Table  2  Costs  (D  )  according  to  category  for  patient  A.
Category  NHI  Publicly  funded
organizations
Patient  and
private  insurance
Total
Prostheses  281,595  0  0  281,595
Specialized  equipment 11,867  78,810  19,084  109,760
Education  0  100,315  0.00  100,315
Home  help  0  69,735  12,364  82,099
Revenue  loss  0  21,553  55,661  77,214
Hospital  care  49,354  1325  8016  58,694
Rehabilitative  care  28,050  400  2311  30,761
Ambulatory  care  23,636  404  4398  28,437
Total  discounted  cost  394,501  272,541  101,833  768,875
Total  non-discounted
cost
739,547  540,812  173,134  1,453,492
Alternative  (CKD)
scenario  discounted
cost
1,106,033  272,541  101,972  1,480,546
Alternative  (CKD)
scenario
non-discounted  cost
2,655,462  540,812  173,284  3,369,558
Table  3  Costs  (D  )  according  to  category  for  patient  B.
Category  NHI  Publicly  funded
organizations
Patient  and
private  insurance
Total
Hospital  care 38,373  634  6954  45,961
Rehabilitative  care 34,358  500  2797  37,655
Shunt  revision 15,506  0  123  15,630
Ambulatory  care  8613  2486  7824  18,923
Special  equipment  34,697  39,446  56,517  130,660
Education  835,922  0  0  835,922
Revenue  loss  0  29,135  130,110  159,244
Home  help  0  8719  2453  11,172
Full-time  residential
care
0 617,269  52,039  669,308
Total  discounted  cost  967,469  698,189  258,817  1,924,475
Total  non-discounted
cost
1,364,589  2,110,105  447,163  3,921,587
Alternative  scenario
discounted  cost
1,339,029  659,324  268,898  2,267,251
Alternative  scenario 2,126,648  1,984,828  467,741  4,579,218
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ydrocephalus.  The  latter  was  treated  by  the
nsertion of  a  ventriculoperitoneal  shunt.  After  a 1-
onth stay  in  the  PICU,  the  patient  was  transferred
o the  pediatric  ward  where  she  stayed  for  an  addi-
ional month.  During  her  stay  at  the  hospital,  her
arents  stayed  in  the  hospital’s  Parents  House.
Blood analysis  was  performed  to  identify  the  bac-
erium responsible  for  the  infection.  The  serogroup
135 meningococcus  was  identiﬁed,  and  chemo-
rophylaxis  was  prescribed  to  close  contacts  of  the
atient (nursery  school,  family  and  friends)  to  avoid
acterial  transmission  and  development  of  other
t
o
t
wases.  Additionally,  these  close  contacts  were  vac-
inated with  a  tetravalent  A,  C,  Y,  W135  conjugate
accine.
Once discharged  from  the  hospital,  patient  B  was
ransferred  to  a  rehabilitation  center  for  5  months,
hich she  attended  5 days  a  week,  where  she  was
ared for  by  an  occupational  therapist.  She  also
onsulted  a neurosurgeon  for  follow-up  for  her  ven-
riculoperitoneal  shunt.  Regular  surgical  revisions
f the  ventriculoperitoneal  shunt  were  required
hroughout the  patient’s  life.  A  ﬁle  at  the  MDPH
as created  for  the  patient  to  obtain  ﬁnancial  aid
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for  the  care  and  support  that  was  not  reimbursed  by
public health  insurance  through  the  PCH.  The  reha-
bilitative  care  physician  also  prepared  a  report  to
provide evidence  of  chronic  disease  in  order  for  the
patient  to  claim  a  100%  reimbursement  for  medical
care.
Once  the  patient  had  returned  home,  her  pedia-
trician  coordinated  her  care  and  visits  to  specialist
health professionals  (physical  therapist,  psychomo-
tor specialist,  occupational  therapist,  etc.).  A  home
helper was  employed  for  17  months.  As  patient  B
was unable  to  walk,  she  had  an  electric  wheelchair
and a  medical  stroller,  which  were  replaced  when
she was  5  years  old  by  a  manual  wheelchair.  She  had
a support  trunk  corset  during  growth.  Patient  B  was
in substantial  pain,  resulting  in  daily  doses  of  anal-
gesic medication.  Additionally,  cerebral  lesions  led
to her  becoming  incontinent.  Patient  B  was  sent  to
a specialist  school  called  the  Medical-Educational
Institute  (Institut  Médico-Educatif,  IME)  from  age
5 to  20.  Transportation  between  the  rehabilitation
center or  IME  and  the  patient’s  home  was  included
in the  daily  cost  of  the  rehabilitation  center.
Transportation  from  the  patient’s  home  to  health
professional  visits  was  provided  by  the  patient’s
parents, and  the  expenses  were  covered  by  the  NHI.
Patient  B  was  one  of  2  children  in  a  two-parent
household.  Her  mother  and  father  worked  full-time
and both  earned  the  mean  French  salary.  When
patient B  became  ill,  her  mother  stopped  working
for 7  months  and  then  returned  to  work  part-
time until  her  child  was  20  years  old.  Because  of
their ﬁnancial  situation,  the  family  beneﬁted  from
parental  leave  payments  for  6  months  and  then
received basic  Handicapped  Child  Education  Aid
until the  patient  was  20  years  old.  When  patient
B turned  20  years  old,  she  was  placed  in  full-time
residential care.  She  died  at  55.
t
(
eed  lifelong  costs  (case  A).
In  an  alternative  scenario,  patient  B also  had
harmacologically treated  epilepsy  and  profound
eafness. She  was  followed  by  a  neurologist.  Her
pileptic  episodes  consisted  of  an  acute  epileptic
ttack 3  times  a  year  requiring  hospitalization  for
ach attack.  Her  pharmacological  treatment  led
o treatment-induced  constipation,  and  she  initi-
ted treatment  with  a constipation  drug.  Patient  B’s
rofound deafness  required  both  cochlear  implants
one  in  each  ear),  which  were  implanted  during  the
cute phase,  as  well  as  regular  consultations  with
he surgeon  and  speech  specialist.  The  external
art of  the  implant  was  replaced  every  5 years.
osts related  to  case  B
he total  discounted  cost  was  D  1,924,475  in
he scenario  without  epilepsy  or  deafness  (lower
ound: D  1,279,617;  upper  bound:  D  2,740,387)
Table  3). With  the  addition  of  epilepsy  and  deaf-
ess, the  total  discounted  cost  increased  slightly
rom D  1,924,475  to  D  2,267,251.
In the  initial  scenario,  the  most  important  cost
river was  the  cost  of  education  (D  835,922;  43.4%),
ollowed  by  the  cost  of  full-time  residential  care
D 669,308;  34.8%).  The  NHI  covered  the  largest
roportion of  the  total  cost  (D  967,469;  50.3%),  fol-
owed by  publicly  funded  organizations  (D  698,189;
6.3%) and  by  the  patient’s  family  and/or  private
nsurance  (D  258,817;  13.4%).  For  the  NHI,  the  cost
f education  was  the  main  expense  (D  835,922;
6.4%) (of  note,  IME  costs  are  100%  reimbursed).  For
ublicly funded  organizations,  full-time  residen-
ial care  was  the  main  expense  (D  617,269;  88.4%),
nd for  the  patient’s  family  and  private  insurance,
he parents’  revenue  loss  was  the  main  expense
D 130,110;  50.3%).
In the  scenario  in  which  the  patient  experienced
pilepsy and  deafness,  more  than  half  of  the  total
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ost  was  covered  by  the  NHI  (D  1,339,029;  59.1%),
he publicly  funded  organizations  covered  the  next
argest proportion  of  the  total  cost  (D  659,324;
9.1%), followed  by  the  patient  and/or  private
nsurance (D  268,898;  11.9%).
The mean  annual  discounted  total  cost  was
 36,311  (lower  bound:  D  24,144;  upper  bound:
 51,705).  The  ﬁrst  year  represented  8.3%  of  the
otal  cost  and  was  the  year  with  the  highest  cost
D 160,648)  because  of  the  initial  hospitalization,
ehabilitative  care  and  purchase  of  specialized
quipment (Fig.  2).  When  epilepsy  and  deafness
ere added  to  the  scenario,  the  mean  annual  dis-
ounted  cost  total  totaled  D  42,778  (lower  bound:
 30,503;  upper  bound:  D  58,065).
iscussion
verall,  a  severe  case  of  IMD  with  purpura  ful-
inans and  leg  amputation  was  estimated  to
e associated  with  a  lifelong  discounted  cost  of
pproximately  D  770,000  in  France.  If  the  con-
equences were  more  serious,  such  as  if  kidney
njury/disease occurred  due  to  purpura  fulminans,
he total  discounted  cost  more  than  doubled  to
 1.5  million.  In  our  study,  a  case  of  IMD  with
evere neurological  sequelae  resulted  in  a  lifelong
iscounted  cost  of  D  1,924,475  in  France.  Adding
rofound deafness  and  epilepsy  increased  this
ost to  D  2,267,251.  This  study  also  showed  that
esource consumption  was  greater  in  the  year
ollowing the  onset  of  symptoms;  our  results
ndicated that  the  costs  totaled  about  D  160,000
or the  ﬁrst  year  regardless  of  the  type  of  IMD.  The
HI  covered  approximately  half  of  the  total  cost  of
are regardless  of  the  case  studied  (case  A  or  case
), publicly  funded  organizations  one  third  and  the
atient or  private  insurance  covered  the  remaining
ost. The  main  driver  of  cost  was  the  prostheses
c
a
m
aed  lifelong  costs  (case  B).
n  the  case  of  purpura  fulminans  and  the  pedi-
tric and  full-time  residential  care  in  the  case  of
eningitis  with  severe  neurological  sequelae.
This study  is  the  ﬁrst  to  estimate  the  costs  associ-
ted with  lifelong  IMD  in  France  and  was  conducted
n response  to  an  identiﬁed  need  for  which  the
cientiﬁc literature  did  not  supply  adequate  infor-
ation. The  study  methodology  was  adapted  from
hat of  a  study  performed  in  the  UK  in  2013  by
he Meningitis  Research  Foundation  (MRF),  and  the
esults of  this  study  are  consistent  with  theirs,
lthough the  costs  were  slightly  lower.  Indeed,  they
stimated  that  the  total  discounted  cost  to  the  UK
overnment  of  a severe  case  of  IMD  over  70  years
ould  be  £1,360,000  to  £1,720,000  [11]. The  MRF
lso estimated  severe  IMD  cases  to  be  associated
ith a  cost  of  £160,000  to  £200,000  in  the  ﬁrst  year
or the  NHI/Personal  Social  Services  (PSS),  while
e estimated  these  costs  to  be  D  160,000.  These
ifferences may  partly  be  explained  by  the  slightly
ess severe  nature  of  the  cases  in  our  study  (i.e.,  in
ur study  the  patient  with  purpura  fulminans  was
 years  old  and  had  both  legs  amputated  below  the
nee, whereas  the  MRF  study  described  a 10-month-
ld with  one  arm  and  both  legs  amputated  above
he knee)  and  the  shorter  time  horizons  (71  and  52
ears in  scenarios  A  and  B,  respectively,  versus  70
ears in  the  English  study).  A  similar  study  has  also
een conducted  in  Spain  using  the  same  methodol-
gy [13]. The  results  of  the  Spanish  study  showed
 total  cost  of D  1,200,000  and  D  1,400,000  over  70
ears. They  estimated  that  IMD  cases  are  associated
ith a cost  of  D  197,000  and  D  155,000  in  the  ﬁrst
ear.
This study  has  several  strengths.  The  method-
logy used  is  that  of  the  MRF,  which  enables
omparison of  the  results.  Cases  A  and  B  were
dapted and  validated  by  national  experts  in  the
anagement  of  IMD  and  the  management  of  dis-
bility. Moreover,  the  sequelae  described  in  the
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scenarios  reﬂect  what  has  been  observed,  as  shown
in a recent  literature  review  [14].
A detailed  cost  study  was  performed  to  incor-
porate all  of  the  costs  associated  with  the
management of  IMD.  Total  costs  were  explored
from different  perspectives  and  were  discounted  to
reduce the  impact  of  events  that  occur  further  in
the future,  in  accordance  with  the  recommenda-
tions for  the  good  practice  of  health-economics  in
France. Sensitivity  analyses  were  conducted  to  esti-
mate the  uncertainty  concerning  the  main  results,
given the  variability  in  unit  costs.  Thus,  the  results
of this  study  can  be  used  by  health  economists
and modelers  in  full  cost-effectiveness  evaluations
to better  represent  the  lifetime  costs  of  treating
severe disease.
Nonetheless,  our  study  has  some  limitations.  The
costs of  CKD  were  obtained  from  the  Blotière  et  al.
study published  in  2010  [15].  However,  little  infor-
mation about  the  cost  was  provided  in  this  study,
which  could  potentially  have  led  to  a  slight  under-
estimation  of  certain  costs.  Finally,  some  costs  were
not included  in  our  study  as  they  were  very  difﬁcult
to measure  (e.g.,  child  care  for  other  children  in  the
family during  consultations  and  hospitalizations  or
indirect costs  related  to  loss  of  patient  autonomy).
Although the  severity  of  IMD  varies  greatly  from
one case  to  another,  from  complete  recovery  to
very severe  sequelae,  which  explains  the  difﬁculty
in evaluating  the  cost  of  IMD,  this  study  ﬁlls  a  gap  in
the body  of  knowledge  on  the  care  and  costs  of  IMD
and its  sequelae.  Our  study  shows  that  the  man-
agement of  such  patients  is burdensome  in  terms
of disability  and  expenditure  for  health  insurance,
families and  government  agencies.  Given  the  ﬁnan-
cial impact  of  IMD  and  its  sequelae,  this  study
emphasizes the  fact  that  it  is  important  to  include
all of  the  health  dimensions  (acute  disease,  seque-
lae) and  to  adopt  all  of  the  perspectives  within
health-economic  evaluations  when  designing  pre-
vention strategies  for  IMD.
Although  the  incidence  of  IMD  in  France  remains
stable, it  is  important  to  maintain  a  policy  to
prevent  IMD  through  informational  campaigns  and
vaccination  programs.  Recently,  the  ﬁrst  vaccine
with broad-spectrum  protection  against  serogroup
B meningococcus  has  been  approved  in  Europe,
which represents  an  opportunity  to  signiﬁcantly
decrease the  burden  of  severe  IMD  cases.Funding
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